
Axonics, Inc. – NASDAQ:AXNX
Axonics stock price monthly change
Axonics stock price quarterly change
Axonics stock price yearly change
Axonics key metrics
Market Cap | 3.62B |
Enterprise value | 2.47B |
P/E | -44.77 |
EV/Sales | 9.05 |
EV/EBITDA | -51.45 |
Price/Sales | 9.77 |
Price/Book | 4.69 |
PEG ratio | -1.43 |
EPS | -0.32 |
Revenue | 316.94M |
EBITDA | 28.18M |
Income | -15.95M |
Revenue Q/Q | 29.38% |
Revenue Y/Y | 7.10% |
Profit margin | -21.81% |
Oper. margin | -15.49% |
Gross margin | 72.22% |
EBIT margin | -15.49% |
EBITDA margin | 8.89% |
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAxonics stock price history
Axonics stock forecast
Axonics financial statements
Jun 2023 | 22.70M | -7.34M | -32.34% |
---|---|---|---|
Sep 2023 | 93.1M | 3.92M | 4.22% |
Dec 2023 | 109.73M | 6.57M | 5.99% |
Mar 2024 | 91.40M | -19.11M | -20.91% |
Sep 2025 | 137.64M | 12.05M | 8.76% |
---|---|---|---|
Oct 2025 | 136.91M | 9.82M | 7.17% |
Dec 2025 | 156.76M | 14.04M | 8.96% |
Mar 2026 | 126.46M | -2.01M | -1.59% |
Analysts Price target
Financials & Ratios estimates
Jun 2023 | 648985000 | 33.28M | 5.13% |
---|---|---|---|
Sep 2023 | 660747000 | 50.12M | 7.59% |
Dec 2023 | 719923000 | 82.35M | 11.44% |
Mar 2024 | 715561000 | 88.46M | 12.36% |
Jun 2023 | -19.20M | -68.62M | -6.76M |
---|---|---|---|
Sep 2023 | 12.34M | -11.05M | 878K |
Dec 2023 | 5.63M | -37.92M | 578K |
Mar 2024 | -9.23M | 138.23M | 248K |
Axonics alternative data
Aug 2023 | 610 |
---|---|
Sep 2023 | 610 |
Oct 2023 | 610 |
Nov 2023 | 610 |
Dec 2023 | 610 |
Jan 2024 | 610 |
Feb 2024 | 610 |
Mar 2024 | 797 |
Apr 2024 | 797 |
May 2024 | 797 |
Jun 2024 | 797 |
Jul 2024 | 797 |
Axonics other data
Period | Buy | Sel |
---|---|---|
Feb 2023 | 0 | 23321 |
Mar 2023 | 0 | 15000 |
Apr 2023 | 0 | 22001 |
May 2023 | 0 | 7999 |
Jul 2023 | 0 | 1500 |
Aug 2023 | 0 | 14769 |
Sep 2023 | 0 | 7675 |
Dec 2023 | 0 | 8000 |
Jan 2024 | 0 | 98451 |
Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
---|---|---|---|---|---|---|---|
Option | SAMA RINDA officer: Chief Op.. | Common Stock | 28,000 | N/A | N/A | ||
Option | KEESE KARI LEIGH officer: Chief Financial Officer | Common Stock | 6,167 | N/A | N/A | ||
Option | SAMA RINDA officer: Chief Op.. | Performance-Based Restricted Stock Units | 17,500 | N/A | N/A | ||
Option | NOBLETT KAREN officer: Chief Me.. | Common Stock | 27,500 | N/A | N/A | ||
Sale | NOBLETT KAREN officer: Chief Me.. | Common Stock | 11,288 | $67.74 | $764,604 | ||
Option | NOBLETT KAREN officer: Chief Me.. | Performance-Based Restricted Stock Units | 15,000 | N/A | N/A | ||
Option | WOOCK JOHN officer: EVP, Chief Mktg/Strtgy.. | Common Stock | 28,000 | N/A | N/A | ||
Sale | WOOCK JOHN officer: EVP, Chief Mktg/Strtgy.. | Common Stock | 15,899 | $67.74 | $1,076,935 | ||
Option | WOOCK JOHN officer: EVP, Chief Mktg/Strtgy.. | Performance-Based Restricted Stock Units | 17,500 | N/A | N/A | ||
Option | FORD ALFRED J JR officer: Chief Co.. | Common Stock | 25,500 | N/A | N/A |
Quarter | Transcript |
---|---|
Q3 2023 30 Oct 2023 | Q3 2023 Earnings Call Transcript |
Q2 2023 27 Jul 2023 | Q2 2023 Earnings Call Transcript |
Q1 2023 1 May 2023 | Q1 2023 Earnings Call Transcript |
Q4 2022 1 Mar 2023 | Q4 2022 Earnings Call Transcript |
August MDA Breakout Stocks Week 33 - 2023: Facing The Largest Negative Signal Since February
July MDA Breakout Stocks Week 29 - 2023: High-Frequency Gainers To Give You An Edge
Axonics: Q1 Fall Provides Great Entry Point
Axonics: Reaffirm Buy Following Q3 Strengths, Guidance Upgrade
Axonics: Medical Devices Play
Axonics Stock Is A Buy Amid Current Capex Cycle
ShockWave Medical: A Hidden Gem In The Medical Device Sector
Axonics: A Strong Medical Device Play With Significant Revenue Growth Opportunities
The Stocks To Focus On Today
-
When is Axonics's next earnings date?
Unfortunately, Axonics's (AXNX) next earnings date is currently unknown.
-
Does Axonics pay dividends?
No, Axonics does not pay dividends.
-
How much money does Axonics make?
Axonics has a market capitalization of 3.62B and it's past years’ income statements indicate that its last revenue has increased compared to the previous period by 33.86% to 366.38M US dollars.
-
What is Axonics's stock symbol?
Axonics, Inc. is traded on the NASDAQ under the ticker symbol "AXNX".
-
What is Axonics's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Axonics?
Shares of Axonics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Axonics's key executives?
Axonics's management team includes the following people:
- Mr. Raymond W. Cohen Chief Executive Officer & Director(age: 66, pay: $1,030,000)
- Mr. Danny L. Dearen Pres & Chief Financial Officer(age: 62, pay: $738,900)
- Dr. Karen L. Noblett M.D., M.A.S. Chief Medical Officer(age: 62, pay: $651,400)
- Mr. Rinda K. Sama Chief Operating Officer(age: 46, pay: $644,730)
- Mr. Alfred J. Ford Jr. Chief Commercial Officer(age: 54, pay: $569,360)
-
How many employees does Axonics have?
As Jul 2024, Axonics employs 797 workers.
-
When Axonics went public?
Axonics, Inc. is publicly traded company for more then 6 years since IPO on 31 Oct 2018.
-
What is Axonics's official website?
The official website for Axonics is axonics.com.
-
Where are Axonics's headquarters?
Axonics is headquartered at 26 Technology Drive, Irvine, CA.
-
How can i contact Axonics?
Axonics's mailing address is 26 Technology Drive, Irvine, CA and company can be reached via phone at +94 93966322.
Axonics company profile:

Axonics, Inc.
axonics.comNASDAQ
797
Medical - Devices
Healthcare
Axonics, Inc., a medical technology company, engages in the development and commercialization of sacral neuromodulation (SNM) systems. The company's SNM systems are used to treat patients with overactive bladder, including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence and non-obstructive urinary retention. Its proprietary rechargeable SNM System (r-SNM) delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of bladder and bowel dysfunction. The company also offers Bulkamid, a urethral bulking agent to treat female stress urinary incontinence. It sells its products through a direct salesforce and distributors in the United States, the United Kingdom, Germany, the Netherlands, Nordic countries, and internationally. The company was formerly known as Axonics Modulation Technologies, Inc. and changed its name to Axonics, Inc. in March 2021. Axonics, Inc. was incorporated in 2012 and is based in Irvine, California.
Irvine, CA 92618
CIK: 0001603756
ISIN: US05465P1012
CUSIP: 05465P101